AERI - アエリ―・ファ―マシュ―ティカルズ （Aerie Pharmaceuticals Inc.）

Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced […] The post Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business appeared first on AiThority .

Aerie Pharmaceuticals'' (AERI) likely last day of trading on the Nasdaq will be on Nov. 18 as part of its merger with Alcon (ALC).

Aerie Pharmaceuticals press release (AERI): Q3 Non-GAAP EPS of -$0.27 beats by $0.16.Revenue of $36.1M (+23.2% Y/Y) beats by $0.8M.Cash, cash equivalents, and investments were…

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. “Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class

The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore advancements in ophthalmic treatments and variety of

Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced […] The post Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business appeared first on AiThority .

Aerie Pharmaceuticals'' (AERI) likely last day of trading on the Nasdaq will be on Nov. 18 as part of its merger with Alcon (ALC).

Aerie Pharmaceuticals press release (AERI): Q3 Non-GAAP EPS of -$0.27 beats by $0.16.Revenue of $36.1M (+23.2% Y/Y) beats by $0.8M.Cash, cash equivalents, and investments were…

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. “Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class

The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore advancements in ophthalmic treatments and variety of

Aerie Pharmaceuticals (AERI) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.The consensus EPS Estimate is -$0.55 (compared to -$0.83 in year…

https://www.investing.com/news/pro/aerie-pharma-pt-lowered-to-12-at-truist-securities-432SI-2859306

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m.… Read More »Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to

Aerie Pharmaceuticals Inc. (NASDAQ:AERI)’s traded shares stood at 0.54 million during the last session, with the company’s beta value hitting 0.43. At the close of trading, the stock’s price was $8.50, to imply a decrease of -0.93% or -$0.08 in intraday trading. The AERI share’s 52-week high remains $17.21, putting it -102.47% down since that … Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Is Currently -102.47 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. Read More »